Research from Baker et al. demonstrated a strong association between the presence of metabolic syndrome and lower response rates to advanced therapies in patients with RA.
Stay Current on Coding Guidelines with ACR Lunch-and-Learns
Available topics include CPT telemedicine code sets, G2211 coding updates, evolving HIPAA guidelines, evaluation and management (E/M) coding and billing strategies.
CMS to Host Town Halls on Medicare Drug Price Negotiation Program
These events will provide a critical opportunity for patients, caregivers, patient organizations, clinicians and researchers to offer input on the drugs selected for the second cycle of negotiations.
RheumPAC Announces New Donor Perks for 2025
RheumPAC contributions enable the ACR to educate key legislators and their staff about the critical issues rheumatologists and rheumatology care team members face.
Rheum for Everyone, Episode 17: ‘All the Lonely People’(video)
In this episode of his monthly video series for The Rheumatologist, physician editor Dr. Bharat Kumar talks about isolation and its impact on our patients with rheumatic disease, and the rheumatologist’s role in combating it.
Ekemini A. Ogbu, MD, MSc, FAAP, Leads the Pediatric Rheumatology Committee
The new chair of the ACR’s Pediatric Rheumatology Committee, Ekemini A. Ogbu, MD, MSc, FAAP, describes how helping children and families navigate complex care brings a sense of fulfillment, purpose and “just joy.”
Deucravacitinib Promising for PsA
Results from two studies found that deucravacitinib improved the signs and symptoms of patients with psoriatic arthritis who were biologic disease-modifying anti-rheumatic drug naive and those previously treated with a tumor necrosis factor α inhibitor.
How RheumPAC Is Supporting You in Uncertain Times
As the new administration enacts policies that impact you and the care you provide to your patients, RheumPAC is working to inform key lawmakers of the downstream effects of these unilateral actions. Learn more about RheumPAC’s role in the ACR’s advocacy efforts.
FDA Approval Sought for 2 Pediatric Indications for Guselkumab
The FDA is reviewing supplemental biologics license applications for guselkumab to treat children with juvenile psoriatic arthritis and moderate to severe plaque psoriasis.
Rheumatologist Elected to Key AMA Committee That Helps CMS Set Medicare Reimbursements
Luke Barré, MD, MPH, RhMSUS, has been elected to the American Medical Association’s Relative Value Update Committee. He is the second rheumatologist to hold the seat in recent years and will ensure representation of the specialty during valuation of physician services.
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 814
- Next Page »